Myfanwy Graham

Associate Investigator - University of Newcastle

Collaborative research with impact:
Myfanwy is a current Fulbright scholar based at the University of Southern California and is conducting a multinational comparison of medicinal cannabis policy and patient outcomes.

As an ACRE associate investigator, Myfanwy has led several medicinal cannabis research projects, with a focus on clinician reported outcomes and collaboratively developed the NSW cannabis medicine prescribing guidance documents.

Myfanwy's research interests include medicinal cannabis, medical and allied health professional education, pharmacovigilance, and personalised medicine.

Clinical role – Knowledge translation:
Myfanwy was the principal specialist medicines information pharmacist of the New South Wales Cannabis Medicines Advisory Service (CMAS) that operated between 2018 and mid-2022, an innovative NSW Government-funded cannabis medicines advisory service for medical practitioners. The service model, led by a clinical pharmacologist and pharmacist, provided comprehensive patient-specific and evidence-based information to support health professionals in prescribing and patient-care decisions. Under this leadership, the service delivered sustained, exceptional outcomes and gained national and international recognition.

Myfanwy’s ongoing engagement and collaborations with national and international researchers, stakeholders, regulatory bodies and policymakers supports the progression of knowledge about medicinal cannabis and the translation of research findings into clinical practice. Myfanwy has collaboratively developed and provided subject matter expert review of several state and national medicinal cannabis educational resources.

Multidisciplinary teaching experience:
Myfanwy holds an academic appointment at the University of Newcastle in the School of Medicine and Public Health and has worked in multidisciplinary health professional training and education since 2009.

Myfanwy is a member of the ACRE Community of Practice for Cannabis Medicines and Dementia and the ACRE Capacity Building Group.